SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA - ADCT
New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether ADC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On September 9, 2022, Morgan Stanley downgraded the Company's stock to Equal Weight from Overweight, citing market penetration concerns regarding the Company's Zynlonta product.
On this news, ADC's stock price fell $0.35 per share, or 5.37%, to close at $6.17 per share on September 9, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137596